NCT04792398View on ClinicalTrials.gov

Bruxism Xeomin® Intervention Trial

PHASE4UnknownINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

May 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions

Sleep Bruxism, Adult

Interventions

DRUG

Incobotulinumtoxin A (BTX A) Xeomin®

Injections into the masseter muscles bilaterally (25 Units per muscle applied with 2 injections in each muscle)

Trial Locations (1)

8032

University of Zurich, Center of Dental Medicine, Zurich

Sponsors

Collaborators (1)

Merz Pharmaceuticals

All Listed Sponsors

collaborator

Merz Pharmaceuticals

INDUSTRY

lead

Dominik Ettlin

OTHER

NCT04792398 - Bruxism Xeomin® Intervention Trial | Biotech Hunter | Biotech Hunter